Última hora

ESAtaque en evento LGBT+ de Berlín: 1 muerto y 16 heridos ESIncendio forestal en Fermoselle (Zamora): Evacuadas siete localidades y declarado el nivel máximo de gravedad ESTerremoto en Japón: sube a 18 el número de muertos tras el sismo de magnitud 7,1 en Kumamoto ESIncendios en la Península Ibérica: Más de 115.000 personas evacuadas o confinadas ESSotillo de la Adrada, un pueblo vacío tras la evacuación por los incendios en Ávila y Madrid ESJuez autoriza análisis de cuentas de Zapatero y su entorno por sospechas de blanqueo ESIncendio en La Vall d'Uixó: Tania Baños describe los momentos más tensos y destaca la solidaridad ciudadana ESEl Bosque Encantado, un milagro entre las llamas en San Martín de Valdeiglesias ESLa Privatización de la Copa del Mundo: Un Terremoto en el Fútbol ESInvestigación apunta a maquinaria pesada como origen del incendio en España ESAtaque en evento LGBT+ de Berlín: 1 muerto y 16 heridos ESIncendio forestal en Fermoselle (Zamora): Evacuadas siete localidades y declarado el nivel máximo de gravedad ESTerremoto en Japón: sube a 18 el número de muertos tras el sismo de magnitud 7,1 en Kumamoto ESIncendios en la Península Ibérica: Más de 115.000 personas evacuadas o confinadas ESSotillo de la Adrada, un pueblo vacío tras la evacuación por los incendios en Ávila y Madrid ESJuez autoriza análisis de cuentas de Zapatero y su entorno por sospechas de blanqueo ESIncendio en La Vall d'Uixó: Tania Baños describe los momentos más tensos y destaca la solidaridad ciudadana ESEl Bosque Encantado, un milagro entre las llamas en San Martín de Valdeiglesias ESLa Privatización de la Copa del Mundo: Un Terremoto en el Fútbol ESInvestigación apunta a maquinaria pesada como origen del incendio en España

Iniciar sesión

weight_loss_drugs

Estable28 noticias15 fuentesÚltima actualización: hace 6 días

Temas relacionadosGLP-1 Wegovy weight-loss drugs Ozempic semaglutide weight loss drugs pharmaceuticals Mounjaro

Últimas noticias

Australia warns on Ozempic, Mounjaro eye disorder risk

Salud·hace 6 díasResumen IA

Australia warns on Ozempic, Mounjaro eye disorder risk

Australia's Therapeutic Goods Administration (TGA) has warned about a "rare but severe" eye disorder, non-arteritic anterior ischaemic optic neuropathy (NAION), linked to type 2 diabetes and obesity treatments like Ozempic and Mounjaro. The warning, based on 36 reported cases, advises patients to seek urgent medical attention for sudden vision loss but not to stop treatment without consulting a doctor.

3 min de lectura

Weight-Loss Drugs Create "Significant Opportunity" for Aesthetics Company Galderma

23/7/2026Resumen IA

Weight-Loss Drugs Create "Significant Opportunity" for Aesthetics Company Galderma

Galderma CEO Flemming Ørnskov stated that the increased use of weight-loss drugs like Ozempic and Wegovy presents a "significant opportunity" for the aesthetics company, particularly in mitigating facial sagging. The company reported nearly 25% sales growth, with U.S. growth outpacing other regions at 32%.

1 min de lectura

Novo Nordisk Sues Eli Lilly Over 'Misleading' Weight-Loss Drug Ads

Business·22/7/2026Resumen IA

Novo Nordisk Sues Eli Lilly Over 'Misleading' Weight-Loss Drug Ads

Novo Nordisk is suing Eli Lilly, alleging "false and misleading" advertisements for its weight-loss and anti-diabetes treatments, Zepbound and Mounjaro. Novo Nordisk claims Lilly used outdated studies comparing its highest doses against lower doses of Novo Nordisk's drugs, creating a deceptive impression of superiority. Eli Lilly defends its ads, citing the Surmount-5 trial as the only direct comparison.

Guardian Business

1 min de lectura

Novo Nordisk Sues Eli Lilly Over Alleged False Advertising of Weight-Loss Drugs

Business·22/7/2026Resumen IA

Novo Nordisk Sues Eli Lilly Over Alleged False Advertising of Weight-Loss Drugs

Novo Nordisk has filed a lawsuit in the US against Eli Lilly, accusing its rival of false advertising regarding the superiority of its weight-loss drugs, Mounjaro and Zepbound. Novo Nordisk claims Eli Lilly compared lower doses of Novo Nordisk's drugs with higher doses of its own, omitting newer options.

1 min de lectura

Biotech Firms Explore GLP-1 Weight-Loss Drugs for Cats

Business·20/7/2026Resumen IA

Biotech Firms Explore GLP-1 Weight-Loss Drugs for Cats

Two US biotech companies, Akston Biosciences and OKAVA Pharmaceuticals, are testing experimental GLP-1 weight-loss treatments for overweight cats, aiming to bring the blockbuster drug class into pet medicine amidst a growing pet obesity problem and increasing owner spending on pet health.

6 min de lectura

Fashion Runways See Decline in Plus-Size Models Amid Rise of Weight Loss Drugs

Lifestyle·20/7/2026Resumen IA

Fashion Runways See Decline in Plus-Size Models Amid Rise of Weight Loss Drugs

The Fall-Winter 2023 fashion shows saw a significant drop in plus-size models, contrasting with previous seasons' limited progress. This rollback coincides with the widespread availability and discussion of new injectable weight loss medications, prompting concerns about the industry's commitment to body diversity and its potential impact on beauty standards.

11 min de lectura

Weight-loss drugs reshaping UK grocery and eating-out habits

Business·7/7/2026Resumen IA

Weight-loss drugs reshaping UK grocery and eating-out habits

Weight-loss medications like Wegovy and Mounjaro are significantly altering UK consumer spending. Research indicates users spend less on groceries and eating out, shifting purchases towards healthier options and products that mitigate side effects, though spending patterns may revert upon cessation.

3 min de lectura

Anyone Can Launch a Telehealth Clinic Now, Thanks to 'Turnkey' Services

Business·1/7/2026Resumen IA

Anyone Can Launch a Telehealth Clinic Now, Thanks to 'Turnkey' Services

Companies are increasingly using "turnkey" telehealth services to quickly launch virtual clinics, even without prior medical experience. These services handle operations, from staffing to compliance, allowing businesses in various sectors to enter the lucrative health market, raising questions about quality and regulation.

5 min de lectura

India's Slow Adoption of Affordable GLP-1 Weight-Loss Drugs Raises Questions

28/6/2026Resumen IA

India's Slow Adoption of Affordable GLP-1 Weight-Loss Drugs Raises Questions

Nithin Kamath questions India's slow uptake of affordable GLP-1 weight-loss drugs despite rising obesity, citing challenges like long-term adherence and physician conservatism, prompting a cautionary response from Kiran Mazumdar-Shaw emphasizing diet and exercise for non-diabetic, non-obese individuals.

India's Slow Adoption of Weight-Loss Drugs: Challenges and Future Outlook

Salud·26/6/2026Resumen IA

India's Slow Adoption of Weight-Loss Drugs: Challenges and Future Outlook

Despite rising obesity and affordable generic GLP-1 drugs, India lags in adoption. Zerodha co-founder Nithin Kamath attributes this to patient retention issues with weekly injections and conservative doctor prescribing habits. Oral alternatives may boost uptake, suggesting convenience, not price, will drive future acceptance.

2 min de lectura

UPS Invests $48 Million in Temperature-Controlled Facilities for Weight-Loss Drugs

Business·22/6/2026Resumen IA

UPS Invests $48 Million in Temperature-Controlled Facilities for Weight-Loss Drugs

UPS is investing $48 million in 27 temperature-controlled facilities globally to meet the rising demand for GLP-1 weight-loss drugs and other sensitive medications, ensuring they remain within required temperature ranges for patient use.

The Independent World

3 min de lectura

FDA considering tighter controls on GLP-1 weight loss drugs amid illegal imports

Salud·19/6/2026Resumen IA

FDA considering tighter controls on GLP-1 weight loss drugs amid illegal imports

The Food and Drug Administration (FDA) is considering stricter border controls for GLP-1 weight loss drugs due to illegal imports from China and online platforms. The agency is also proposing amendments to the Pharmaceutical Affairs Act to hold online platforms accountable for hosting illegal drug sales.

3 min de lectura

India's Growing Out-of-Pocket Healthcare: Weight-Loss Drugs, Cosmetic Procedures Excluded from Insurance

Business·15/6/2026Resumen IA

India's Growing Out-of-Pocket Healthcare: Weight-Loss Drugs, Cosmetic Procedures Excluded from Insurance

Demand for weight-loss drugs, cosmetic procedures, and wellness treatments is driving out-of-pocket healthcare expenses in India. Most of these, like Botox and anti-obesity drugs, are not covered by standard health insurance unless medically necessary, experts advise understanding policy exclusions and avoiding EMIs for elective treatments.

7 min de lectura

India's Growing Out-of-Pocket Healthcare Expenses: Weight-Loss Drugs, Cosmetic Procedures Excluded from Insurance

Business·15/6/2026Resumen IA

India's Growing Out-of-Pocket Healthcare Expenses: Weight-Loss Drugs, Cosmetic Procedures Excluded from Insurance

Demand for weight-loss drugs, cosmetic procedures, and wellness treatments is driving out-of-pocket healthcare spending in India. Most of these interventions, like Botox and anti-obesity drugs, are not covered by standard health insurance unless medically necessary. Experts advise reviewing policy exclusions and avoiding EMIs for elective treatments.

8 min de lectura

Weight-loss drugs cut UK household grocery bills by £418 annually

Business·10/6/2026Resumen IA

Weight-loss drugs cut UK household grocery bills by £418 annually

GLP-1 weight-loss drug users in Great Britain are saving an average of £418 annually on groceries, with household use nearly tripling in two years to 1.9 million adults. The drugs are impacting food consumption and forcing retailers to adapt.

Guardian Business

3 min de lectura

Canada Approves Generic GLP-1 Injections, Lowering Costs

Business·4/6/2026Resumen IA

Canada Approves Generic GLP-1 Injections, Lowering Costs

Canada has become the first G7 nation to approve generic semaglutide injections, making GLP-1 drugs more accessible and affordable. This move by Novo Nordisk follows similar approvals in India and has already led to price reductions for brand-name medications.

5 min de lectura

Canada Approves Generic GLP-1 Injections, Lowering Costs for Patients

Business·4/6/2026Resumen IA

Canada Approves Generic GLP-1 Injections, Lowering Costs for Patients

Canada has become the first G7 nation to approve generic semaglutide injections, making GLP-1 drugs more accessible and affordable. This move by Novo Nordisk follows similar approvals in India and may pressure US prices, though generics are not expected there until 2032.

5 min de lectura

Weight-loss drugs could prevent thousands of knee replacements annually, study suggests

Salud·2/6/2026Resumen IA

Weight-loss drugs could prevent thousands of knee replacements annually, study suggests

Research indicates that using weight-loss drugs like Mounjaro, Wegovy, and Ozempic for at least three years could significantly reduce the need for knee replacement surgeries, potentially preventing thousands of procedures annually in the US and UK.

3 min de lectura

Weight-loss drugs may cut cancer risk by 30%, studies suggest

Salud·2/6/2026Resumen IA

Weight-loss drugs may cut cancer risk by 30%, studies suggest

New studies presented at a major oncology conference suggest GLP-1 weight-loss drugs could reduce cancer risk by 30%. Research indicates they may lower the likelihood of developing breast cancer, decrease mortality risk in breast cancer patients, and reduce the spread of various cancers.

Guardian International

4 min de lectura

CVS Health to Restore Coverage of Eli Lilly's Weight Loss Drugs

28/5/2026Resumen IA

CVS Health to Restore Coverage of Eli Lilly's Weight Loss Drugs

CVS Health will restore coverage of Eli Lilly's weight loss injection Zepbound on Oct. 1 and add coverage of its new obesity pill Foundayo on June 1, making both GLP-1 medications co-preferred options on its standard commercial formulary, affecting 25-30 million Americans and boosting Lilly's market position against Novo Nordisk.

CNBC US Markets

3 min de lectura

GLP-1 Face: Will Weight-Loss Drugs Redefine Artistic Beauty?

23/5/2026Resumen IA

GLP-1 Face: Will Weight-Loss Drugs Redefine Artistic Beauty?

Experts suggest the rise of weight-loss drugs like Wegovy could influence future art, potentially popularizing a "GLP-1 face" characterized by rapid fat loss, similar to past aesthetic trends. This shift contrasts with historical art that often celebrated fuller figures.

Guardian International

3 min de lectura

Trash-Pop's Rise: Hedonism, Rebellion, and Reclaiming Femininity

22/5/2026Resumen IA

Trash-Pop's Rise: Hedonism, Rebellion, and Reclaiming Femininity

A new wave of female pop stars, including Slayyyter, Kesha, and Tove Lo, are embracing a "trash-pop" aesthetic characterized by hedonistic lyrics, anarchic sexuality, and a "white trash" sensibility. This trend, influenced by early 00s electroclash and reality TV culture, represents a rejection of feminine respectability and a cathartic expression of anger and frustration.

Guardian International

8 min de lectura

Expert Warns Against Misuse of Weight Loss Drugs, Especially for Minors

21/5/2026Resumen IA

Expert Warns Against Misuse of Weight Loss Drugs, Especially for Minors

A Peking Union Medical College Hospital physician advises caution with rapid weight loss methods, including "slimming injections" and diabetes medications. These are prescription drugs with specific indications and potential side effects, requiring specialist evaluation and not for self-purchase or arbitrary use. The expert specifically warns against their use in individuals under 18 due to potential impacts on growth and development.

中国新闻网

1 min de lectura

Pharmaceutical sector at risk from GLP-1 'bubble effect' as weight loss drugs dominate R&D returns

Business·4/5/2026Resumen IA

Pharmaceutical sector at risk from GLP-1 'bubble effect' as weight loss drugs dominate R&D returns

Deloitte research reveals pharmaceutical R&D returns for top 20 companies reached 7% in 2025, the highest in years, driven almost entirely by GLP-1 weight loss and diabetes drugs. However, excluding these assets, returns plummet to just 2.9%. For the first time in 16 years, obesity treatments have surpassed oncology as the largest contributor to late-stage pipeline value, raising concerns about concentrated risk and a potential bubble effect.

2 min de lectura